Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Interferon alpha kinoid - Neovacs

Drug Profile

Interferon alpha kinoid - Neovacs

Alternative Names: Antiferon; IFNalpha kinoid vaccine - Neovacs; IFNα kinoid

Latest Information Update: 17 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Neovacs
  • Developer Department Immunology of Diabetes at Hospital Cochin; Neovacs; sanofi pasteur
  • Class Antihyperglycaemics; Interferons; Recombinant fusion proteins; Skin disorder therapies; Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Dermatomyositis; Systemic lupus erythematosus

Highest Development Phases

  • Phase II Dermatomyositis; Systemic lupus erythematosus
  • Preclinical Type 1 diabetes mellitus
  • Discontinued HIV infections; Sjogren's syndrome

Most Recent Events

  • 30 Oct 2018 Neovacs and CKD Pharmaceuticals intend to file for orphan drug designation in South Korea in 2019
  • 30 Oct 2018 NeoVacs plans a phase III trial for Systemic lupus erythematosus in USA and Europe (IM) in 2018
  • 11 Oct 2018 Neovacs continues the commercialisation and development agreement with Chong Kun Dan Pharmaceuticals in Systemic lupus erythematous and Dermatomyositis in South Korea
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top